On August 9 2023, MACROGENICS ($NASDAQ:MGNX) reported their FY2023 Q2 earnings results showing a total revenue of USD 13.1 million – a decrease of 49.5% year-over-year. Net income for the quarter was significantly improved from the prior year’s -41.3 million, coming in at USD 57.5 million.
Analysis – Macrogenics Intrinsic Value Calculator
GoodWhale is a great tool to analyze MACROGENICS‘s financials. According to our proprietary Valuation Line, the fair value of MACROGENICS share is around $20.9. It means that the current price of MACROGENICS stock, which is $5.0, is undervalued by 76.1%. It provides an opportunity for investors to buy the stock at a discounted price and make a profit in the future. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Macrogenics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Macrogenics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Macrogenics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Macrogenics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Macrogenics’ proprietary technology involves the use of engineered human antibodies to target disease-causing proteins. The company has four product candidates in clinical development for the treatment of various cancers and autoimmune diseases. Macrogenics’ competitors in the antibody therapeutics market include Nuvation Bio, Inc., Adocia, and Tonix Pharmaceuticals Holding Corp.
– Nuvation Bio Inc ($NYSE:NUVB)
Nuvation Bio Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for the treatment of cancer and other serious diseases. Its lead product candidate is rovalpituzumab tesirine, an antibody-drug conjugate (ADC) targeting delta-like protein 3 (DLL3), which is in Phase II clinical development for the treatment of small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), mesothelioma, and pancreatic cancer. The Company is also developing NB-01, a DLL3-targeted ADC for the treatment of SCLC and NSCLC, which is in preclinical development.
Adocia is a company that produces medicines and treatments for diabetes. The company has a market cap of 30.91M as of 2022 and a Return on Equity of 33.93%. Adocia’s products include insulin, GLP-1 analogs, and SGLT2 inhibitors. The company’s products are used to treat type 1 and type 2 diabetes.
– Tonix Pharmaceuticals Holding Corp ($NASDAQ:TNXP)
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company. The company’s focus is on discovering, licensing, acquiring and developing small molecule drugs, biologics and natural product drugs to treat serious neurological, psychiatric and immunologic disorders.
Macrogenics reported their FY2023 Q2 earnings results with total revenue of USD 13.1 million, a decrease of 49.5% compared to the same period last year. Net income for the quarter was reported to be USD 57.5 million, a significant improvement from the prior year’s -41.3 million. Investors should consider the fact that Macrogenics has been able to increase their net income despite a substantial decrease in their revenue for this quarter, and this could be an indication of a strong financial position. Going forward, investors should analyze Macrogenics’ cash flow performance, corporate strategies, and competitive landscape to gain insight into future prospects.